A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

被引：6
|
作者：
Bauer, S. [1 ]
Demetri, G. [2 ]
Jeay, S. [3 ]
Dummer, R. [4 ]
Guerreiro, N. [3 ]
Tan, D. S. [5 ]
Kumar, A. [6 ]
Meille, C. [3 ]
Van Bree, L. [3 ]
Halilovic, E. [7 ]
Wuerthner, J. U. [3 ]
Cassier, P. [8 ]
机构：
[1] Univ Klinikum Essen, Internal Med, Essen, Germany
[2] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Univ Zurich Hosp, Zurich, Switzerland
[5] Natl Canc Ctr, Singapore, Singapore
[6] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[7] Novartis Inst BioMed Res, Cambridge, MA USA
[8] Ctr Leon Berard, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Modeling of pharmacokinetics, thrombocytopenia, plasma GDF-15 levels and tumor kinetics in response to treatment with the p53-HDM2 protein-protein interaction inhibitor NVP-CGM097
    Meille, C.
    Guerreiro, N.
    Bauer, S.
    Cassier, P.
    Demetri, G.
    Dummer, R.
    Tan, D. S.
    Van Bree, L.
    Ramkumar, T.
    Halilovic, E.
    Jeay, S.
    Jullion, A.
    Hourcade-Potelleret, F.
    Wuerthner, J. U.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    [J]. PANCREAS, 2017, 46 (03) : 437 - 437
  • [4] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    [J]. BLOOD, 2010, 116 (21) : 1350 - 1351
  • [5] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    [J]. CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [6] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [7] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    [J]. Investigational New Drugs, 2013, 31 : 409 - 416
  • [8] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [9] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, K. P.
    Mendelson, D. S.
    Tolcher, A. W.
    Patnaik, A.
    Burris, H. A.
    Rasco, D. W.
    Bendell, J. C.
    Gordon, M. S.
    Kato, G.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H. H.
    Woo, T.
    Infante, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS
    Bhadri, Vivek
    Bui, Nam
    Guminski, Alexander
    Oneto, Jose Mejia
    Murthy, Ravi
    Sankhala, Kamalesh
    Saville, M. Wayne
    Srinivasan, Sangeetha
    Steffner, Robert
    Subbiah, Vivek
    Wang, Ding
    Yee, Nathan
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A253 - A254
12345